Meeting
2020 Genitourinary Cancers Symposium
Development of a predictive model of PSA response to a switch from prednisone to dexamethasone in metastatic castrate-resistant prostate cancer patients biochemically progressing on abiraterone.
Authors
Reeta Barua
University of Toronto, Toronto, ON, Canada
Reeta Barua , Cameron Phillips , Vanessa Sarah Arciero , Liying Zhang , Amanda Rahmadian , Seanthel Delos Santos , Shruti Parshad , Urban Emmenegger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 88)
Abstract #
88
Poster Bd #
D12
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer (mCRPC): Results from an expanded access program.
First Author: David Thomson
Poster
2020 Genitourinary Cancers Symposium
Treatment outcomes for metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) following docetaxel (D) for hormone sensitive disease.
First Author: Andrew Lachlan Schmidt
Poster
2019 ASCO Annual Meeting
Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.
First Author: Christophe Massard
Poster
2019 Genitourinary Cancers Symposium
Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
First Author: Christophe Massard